

Psychotropics With Expedited Approvals	
Medication	Indication ¹
Aducanumab (Aduhelm, 2021)	Alzheimer's disease dementia (n = 3285)
Brexanolone (Zulresso, 2019)	Postpartum depression (n = 226)
Deutetrabenazine (Austedo, 2017)	Tardive dyskinesia (n = 404)
Esketamine (Spravato, 2019)	Treatment-resistant depression (n = 1709) Depression with acute suicidality (n = 262)
Pimavanserin (Nuplazid, 2016)	Parkinson's disease psychosis (n = 199)
Valbenazine (Ingrezza, 2017)	Tardive dyskinesia (n = 234)

¹Number of participants in FDA-registration trial(s)

From the Article:
"In Brief: Meds in the Fast Lane"
by **Chris Aiken, MD**

The Carlat Psychiatry Report, Volume: 19, Issue 11&12, November/December 2021

www.thecarlatreport.com